The pharmacokinetics of epirubicin

W. J F Van Der Vijgh; H. Weenen; S. E J M Van Der Poort; A. P R M Osterop; H. M. Pinedo; J. G. McVie

The pharmacokinetics of epirubicin

W. J F Van Der Vijgh, H. Weenen, S. E J M Van Der Poort, A. P R M Osterop, H. M. Pinedo, J. G. McVie

Research output: Contribution to journal › Article › peer-review

Abstract

The pharmacokinetics of epirubicin was studied in patients with soft tissue sarcomas or advanced breast cancer. The epirubicin was given as an i.v. bolus injection of 75 or 90 mg/m². Blood and urine samples were collected at regular time intervals for at least 48 hours. Extraction and high performance liquid chromatography of the samples were done. It was found that epirubicin compared to doxorubicin has a unique glucuronidation pathway which may explain its shorter half-life and its reduced cardiotoxicity.

Original language	English (US)
Pages (from-to)	23-27
Number of pages	5
Journal	Clinical Trials Journal
Volume	24
Issue number	SUPPL. 1
State	Published - 1987
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)

Cite this

@article{5c7f29624ead4bda800c4acaca481649,

title = "The pharmacokinetics of epirubicin",

abstract = "The pharmacokinetics of epirubicin was studied in patients with soft tissue sarcomas or advanced breast cancer. The epirubicin was given as an i.v. bolus injection of 75 or 90 mg/m2. Blood and urine samples were collected at regular time intervals for at least 48 hours. Extraction and high performance liquid chromatography of the samples were done. It was found that epirubicin compared to doxorubicin has a unique glucuronidation pathway which may explain its shorter half-life and its reduced cardiotoxicity.",

author = "{Van Der Vijgh}, {W. J F} and H. Weenen and {Van Der Poort}, {S. E J M} and Osterop, {A. P R M} and Pinedo, {H. M.} and McVie, {J. G.}",

year = "1987",

language = "English (US)",

volume = "24",

pages = "23--27",

journal = "Clinical Trials Journal",

issn = "0009-9325",

publisher = "Elsevier BV",

number = "SUPPL. 1",

}

TY - JOUR

T1 - The pharmacokinetics of epirubicin

AU - Van Der Vijgh, W. J F

AU - Weenen, H.

AU - Van Der Poort, S. E J M

AU - Osterop, A. P R M

AU - Pinedo, H. M.

AU - McVie, J. G.

PY - 1987

Y1 - 1987

N2 - The pharmacokinetics of epirubicin was studied in patients with soft tissue sarcomas or advanced breast cancer. The epirubicin was given as an i.v. bolus injection of 75 or 90 mg/m2. Blood and urine samples were collected at regular time intervals for at least 48 hours. Extraction and high performance liquid chromatography of the samples were done. It was found that epirubicin compared to doxorubicin has a unique glucuronidation pathway which may explain its shorter half-life and its reduced cardiotoxicity.

AB - The pharmacokinetics of epirubicin was studied in patients with soft tissue sarcomas or advanced breast cancer. The epirubicin was given as an i.v. bolus injection of 75 or 90 mg/m2. Blood and urine samples were collected at regular time intervals for at least 48 hours. Extraction and high performance liquid chromatography of the samples were done. It was found that epirubicin compared to doxorubicin has a unique glucuronidation pathway which may explain its shorter half-life and its reduced cardiotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0023543680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023543680&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023543680

SN - 0009-9325

VL - 24

SP - 23

EP - 27

JO - Clinical Trials Journal

JF - Clinical Trials Journal

IS - SUPPL. 1

ER -

The pharmacokinetics of epirubicin

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this